- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02179034
Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1
April 30, 2020 updated by: Yale University
This study is to examine if inhaled doses of menthol that produce low and high cooling effects change the appeal of e-cigarettes containing low and high doses of nicotine in adolescent smokers.
The hypothesis is that the combination of nicotine and menthol, when compared with menthol or nicotine alone, will result in greater increase in liking of an e-cigarette and greater reduction in nicotine withdrawal.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- CMHC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 20 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 18-20 years
- Able to read and write
- Cigarette smoker
- Use of e-cigarettes in the past 30 days
Exclusion Criteria:
- Seeking smoking cessation treatment
- Current/lifetime criteria for dependence on another psychoactive substance -Daily use of alcohol or marijuana or use of any other drugs including cocaine, opiates, stimulants
- Regular use of psychoactive drugs including anxiolytics, antidepressants and other psychostimulants
- Current or past history of psychosis or other psychiatric diagnosis such as major depression
- Any significant current medical condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Tobacco Flavor
In this arm, subjects will receive tobacco flavor- without nicotine (placebo).
Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
|
A low dose of menthol will be added to the tobacco flavor.
A high dose of menthol will be added to the tobacco flavor.
|
|
Active Comparator: Low Dose Nicotine
In this arm, subjects will receive a low dose of nicotine (6 mg/ml) added to the tobacco flavor.
Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
|
A low dose of menthol will be added to the tobacco flavor.
A high dose of menthol will be added to the tobacco flavor.
Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
|
|
Active Comparator: High Dose Nicotine
In this arm, subjects will receive a high dose of nicotine (12 mg/ml) added to the tobacco flavor.
Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
|
A low dose of menthol will be added to the tobacco flavor.
A high dose of menthol will be added to the tobacco flavor.
Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liking/effect score of the e-cigarette
Time Frame: Every 30 min for 120 min during lab session
|
The Drug Effects Questionnaire (Soria et al) will be used to ask about participants' liking/effect of the e-cigarettes smoked during the 4 bouts of e-cigarette puffing during the lab session to determine which menthol dose is most preferred.
A linear mixed-effects regression model wil be used with nicotine group (none, low, high) as between-subject factor, and menthol dose (none, low dose, high dose) as within-subject factor.
|
Every 30 min for 120 min during lab session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum value of money at which the e-cigarette is chosen over money
Time Frame: Every 30 min for 120 min during lab session
|
E-cigarette value will be determined using the Multiple Choice Procedure (Griffiths et al, 1993) to determine the reinforcing value of the e-cigarette.
The MCP involves sampling the e-cigarette and then making a discrete choice between the e-cigarette or a series of monetary values.
|
Every 30 min for 120 min during lab session
|
|
Change scores from baseline in Nicotine Withdrawal
Time Frame: Every 30 min for 120 min during lab session
|
The Minnesota Nicotine Withdrawal Scale (Hughes et al,1986) will be used to assess the magnitude of change in nicotine withdrawal symptoms during the lab session
|
Every 30 min for 120 min during lab session
|
|
Change scores from baseline in Tobacco Craving
Time Frame: Every 30 min for 120 min during lab session
|
The Brief Questionnaire on Smoking Urges (Tiffany & Drobes,1991) will be used to assess the magnitude of change in tobacco craving during the lab session
|
Every 30 min for 120 min during lab session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Dana Cavallo, PhD, Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 23, 2014
Primary Completion (Actual)
July 18, 2016
Study Completion (Actual)
June 12, 2017
Study Registration Dates
First Submitted
June 24, 2014
First Submitted That Met QC Criteria
June 27, 2014
First Posted (Estimate)
July 1, 2014
Study Record Updates
Last Update Posted (Actual)
May 4, 2020
Last Update Submitted That Met QC Criteria
April 30, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Dermatologic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Antipruritics
- Nicotine
- Menthol
Other Study ID Numbers
- 1307012312
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Dependence, Other Tobacco Product
-
Juul Labs, Inc.Rose Research Center, LLCCompletedTobacco Use | Tobacco Smoking | Nicotine Dependence, Other Tobacco ProductUnited States
-
Juul Labs, Inc.CelerionCompletedTobacco Use | Smoking, Tobacco | Nicotine Dependence, Other Tobacco ProductUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedSmoking | Nicotine Dependence | Nicotine Dependence, Other Tobacco ProductUnited States
-
Augusta UniversityRecruitingE-Cig Use | Nicotine Dependence, Other Tobacco Product | Smoking Cessation; Tobacco DependenceUnited States
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruitingNicotine Dependence Tobacco ProductNorway, Czechia
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Indiana UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Dartmouth-Hitchcock Medical CenterCompletedLung Cancer | Bladder Cancer | Cancer of Head and Neck | Nicotine Dependence, Other Tobacco ProductUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Nicotine Dependence | Nicotine Dependence, CigarettesNew Zealand
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)WithdrawnCardiovascular Risk Factor | Nicotine Dependence | Nicotine Dependence, Cigarettes | Nicotine Withdrawal | Tobacco ToxicityUnited States
Clinical Trials on Low Dose Menthol
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Recruiting
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA); Brown University; National Institutes... and other collaboratorsCompletedSmoking (Tobacco) AddictionUnited States
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Postgraduate Institute of Medical Education and...Completed
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed